{"id":"https://genegraph.clinicalgenome.org/r/6a1851d0-9652-4acc-9660-9514dccb0ecfv1.2","type":"EvidenceStrengthAssertion","dc:description":"KCNJ10 was first reported in relation to autosomal recessive EAST (epilepsy, ataxia, sensorineural deafness and kidney salt-wasting tubulopathy) Syndrome in 2009 (Scholl et al. 2009, PMID: 19289823; and Bockenhauer et al., 2009, PMID: 19420365). \nAt 11 least variants (missense and nonsense mutations) have been reported in humans. Evidence supporting this gene-disease relationship includes case level data, and experimental data (biochemical functional, expression level evidence, and a mouse model). In summary, the evidence for this gene is ample, and this gene disease relationship has been replicated for well over three years (since 2009), so the relationship is definitive. ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6a1851d0-9652-4acc-9660-9514dccb0ecf","GCISnapshot":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10067","date":"2023-06-29T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10067","date":"2023-06-29T22:11:22.750Z","role":"Publisher"}],"curationReasonDescription":"Genetic evidence should be scored at 11.8. The GCI counted functional evidence for homozygous variants twice, when this is not what we want to do. ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3970724b-a79a-4628-9835-db461c6d9c85_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3970724b-a79a-4628-9835-db461c6d9c85","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"Bockenhauer et al., 2009: Family 2 (1 individual)","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a6402a9a-73fc-4c12-a568-06f9c7a3e978","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.229G>C (p.Gly77Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118814"}},"firstTestingMethod":"Linkage analysis","phenotypeFreeText":"The patient had sensorineural hearing loss, ataxia, seizures, kidney salt wasting, and trouble speaking. ","phenotypes":["obo:HP_0000127","obo:HP_0001251","obo:HP_0000750","obo:HP_0000407","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"Whole-genome linkage analysis and haplotype reconstruction","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c8cc9a5c-ff3b-4b03-8d80-da13dcd3b777_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6402a9a-73fc-4c12-a568-06f9c7a3e978"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/c8cc9a5c-ff3b-4b03-8d80-da13dcd3b777","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8cc9a5c-ff3b-4b03-8d80-da13dcd3b777_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/c8cc9a5c-ff3b-4b03-8d80-da13dcd3b777_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Xenopus oocytes with this mutation exhibited significantly decreased channel activity compared to the wildtype. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/49eb700d-efe9-4c44-935a-a1b74283eff5_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/49eb700d-efe9-4c44-935a-a1b74283eff5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"Kara et al., 2013","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e7d2cb84-e76f-428b-880b-959325af5ede","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.611G>A (p.Arg204His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1193228"}},"detectionMethod":"Molecular genetic analysis","firstTestingMethod":"Genotyping","phenotypeFreeText":"Seizures, renal salt wasting, delayed speech development, ataxia, sensorineural deafness","phenotypes":["obo:HP_0001250","obo:HP_0000127","obo:HP_0000750","obo:HP_0001251","obo:HP_0000407"],"previousTesting":true,"previousTestingDescription":"Molecular genetics analysis","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ae9e2434-83dd-4dec-aef4-542b099ef05c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/e7d2cb84-e76f-428b-880b-959325af5ede"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/ae9e2434-83dd-4dec-aef4-542b099ef05c","type":"EvidenceLine","calculatedScore":0.2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ae9e2434-83dd-4dec-aef4-542b099ef05c_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/cf66a2cd-f242-43da-bc2e-3ddd784c8cd6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf66a2cd-f242-43da-bc2e-3ddd784c8cd6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"Bockenhauer et al., 2009: Family 1 (4 individuals)","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1da7b810-afd6-412e-bb94-896e25cad586","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.194G>C (p.Arg65Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118807"}},"detectionMethod":"Whole genome linkage analysis and haplotype reconstruction","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Ataxia, sensorineural hearing loss, renal salt wasting, seizures, speech issues","phenotypes":["obo:HP_0000750","obo:HP_0001251","obo:HP_0000127","obo:HP_0000407","obo:HP_0001250"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/2e6ff161-2ef0-4d69-8819-2bbb35fdf5b9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/1da7b810-afd6-412e-bb94-896e25cad586"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/2e6ff161-2ef0-4d69-8819-2bbb35fdf5b9","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e6ff161-2ef0-4d69-8819-2bbb35fdf5b9_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2e6ff161-2ef0-4d69-8819-2bbb35fdf5b9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutation results in a significant reduction in channel activity compared to the wildtype","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/1f192f0d-50dc-4258-ba00-06ad66c31c16_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1f192f0d-50dc-4258-ba00-06ad66c31c16","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"Homozygous missense Val259Stop","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2c260904-9f98-4db1-852d-7d1ceac7b635","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.775del (p.Val259Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913184767"}},"firstTestingMethod":"Genotyping","phenotypeFreeText":"Seizure, ataxia, renal salt wasting, sensorineural deafness","phenotypes":["obo:HP_0000127","obo:HP_0001251","obo:HP_0000407","obo:HP_0001250"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2d289f7d-0124-4431-a1e0-10f7bc4e7ba1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/2c260904-9f98-4db1-852d-7d1ceac7b635"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/2d289f7d-0124-4431-a1e0-10f7bc4e7ba1","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2d289f7d-0124-4431-a1e0-10f7bc4e7ba1_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/2d289f7d-0124-4431-a1e0-10f7bc4e7ba1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutating variant in xenopus oocytes dramatically reduced channel activity. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/9f0f94a1-0a79-40e6-93d7-e5c84e5f7b36_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9f0f94a1-0a79-40e6-93d7-e5c84e5f7b36","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24193250","rdfs:label":"Parrock et al 2013, nonsense","allele":{"id":"https://genegraph.clinicalgenome.org/r/4c07f20d-f4ab-4a5e-aae3-ad0f50f03478","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.272del (p.Val91GlyfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573332901"}},"detectionMethod":"DNA of affected probands was amplified and sequenced. Article just mentions that this variant was found in a proband with east syndrome without giving specific information about the individual. ","firstTestingMethod":"Genotyping","phenotypeFreeText":"Ataxia, sensorineural hearing loss, seizures, renal salt wasting","phenotypes":["obo:HP_0000127","obo:HP_0001250","obo:HP_0000407","obo:HP_0001251"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/1d0d4e77-ea88-4f4c-b152-d4cf71bc4bd8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24193250","allele":{"id":"https://genegraph.clinicalgenome.org/r/4c07f20d-f4ab-4a5e-aae3-ad0f50f03478"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/1d0d4e77-ea88-4f4c-b152-d4cf71bc4bd8","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d0d4e77-ea88-4f4c-b152-d4cf71bc4bd8_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1d0d4e77-ea88-4f4c-b152-d4cf71bc4bd8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This nonsense variant significantly decreased potassium channel activity compared to the wildtype in xenopus oocytes. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/f2c403a6-3144-46fe-8d3f-2855aa20c48f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2c403a6-3144-46fe-8d3f-2855aa20c48f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"4 affected sibs. from Latvia (each homozygous for Arg65Cy)","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/fa69b095-81a0-4c1c-8534-3373922d19bd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.193C>T (p.Arg65Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129068"}},"firstTestingMethod":"Genotyping","previousTesting":true,"previousTestingDescription":"Family genotyping was done. The genotypes of the affected individuals (each homozgyous for the missense mutation Arg65Cys and parents (each heterozygous for the mutation) were determined. A pedigree chart was made. ","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e392fb00-6231-468a-bd96-197ea7edacf5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/fa69b095-81a0-4c1c-8534-3373922d19bd"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/e392fb00-6231-468a-bd96-197ea7edacf5","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e392fb00-6231-468a-bd96-197ea7edacf5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/e392fb00-6231-468a-bd96-197ea7edacf5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Experimental residual activity is less than 20 % of the wildtype","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/8889c6d5-542c-485e-9276-bdf685008edb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8889c6d5-542c-485e-9276-bdf685008edb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"Papavasiliou et al., 2017","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/2c260904-9f98-4db1-852d-7d1ceac7b635"},{"id":"https://genegraph.clinicalgenome.org/r/fa69b095-81a0-4c1c-8534-3373922d19bd"}],"detectionMethod":"Genotyping was done to find the mutations themselves, but phase was not determined.","firstTestingMethod":"Genotyping","phenotypeFreeText":"Seizures, ataxia, sensorineural deafness, cerebral palsy, renal salt-wasting","phenotypes":["obo:HP_0000407","obo:HP_0001251","obo:HP_0001250","obo:HP_0000127","obo:HP_0100021"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/0e802d88-a4dc-489d-be53-5795b898e1fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/fa69b095-81a0-4c1c-8534-3373922d19bd"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/a1ffeaa0-a70f-4dd4-990c-5c44f971ea95_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","allele":{"id":"https://genegraph.clinicalgenome.org/r/2c260904-9f98-4db1-852d-7d1ceac7b635"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/a1ffeaa0-a70f-4dd4-990c-5c44f971ea95","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a1ffeaa0-a70f-4dd4-990c-5c44f971ea95_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a1ffeaa0-a70f-4dd4-990c-5c44f971ea95_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Potassium channel function was notably lower in xenopus oocytes with the variant than in the wildtype (Freudenthal et al., 2011; PMID: 21849804)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/0e802d88-a4dc-489d-be53-5795b898e1fc","type":"EvidenceLine","dc:description":"Loss of function variant should be score at 1.5. There is no functional evidence for it, but I could not record it because it was not published (p.F119GfsTer25). ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e802d88-a4dc-489d-be53-5795b898e1fc_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0e802d88-a4dc-489d-be53-5795b898e1fc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This mutation greatly reduces channel activity compared to the wildtype. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2100b986-fe17-497c-8648-aa87b2282083_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29722015","rdfs:label":"4 affected probands from Latvian family: each Arg65Cy (homo)","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/2100b986-fe17-497c-8648-aa87b2282083","type":"Family","rdfs:label":"4 affected probands from Latvian family: each Arg65Cy (homo)","member":{"id":"https://genegraph.clinicalgenome.org/r/f2c403a6-3144-46fe-8d3f-2855aa20c48f"}},"meetsInclusionCriteria":true,"phenotypeFreeText":"ataxia, seizures, speech difficulties, hearing loss, kidney salt-wasting, behavioral issues","phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0000407","obo:HP_0001251","obo:HP_0001250","obo:HP_0000750"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f2c403a6-3144-46fe-8d3f-2855aa20c48f"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/7b7833b8-b5d6-457f-9650-d5a77ffca268_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19289823","rdfs:label":"Scholl et al: Non-consanguineous family ","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/7b7833b8-b5d6-457f-9650-d5a77ffca268","type":"Family","rdfs:label":"Scholl et al: Non-consanguineous family ","member":{"id":"https://genegraph.clinicalgenome.org/r/577d3f1e-6367-4019-bf69-ae07c58c1b1b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19289823","rdfs:label":"Ala167Val/Arg297Cys; proband from Canada","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/992f37a8-2a04-4ed9-8355-f89bc6c55fae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.500C>T (p.Ala167Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118812"}},{"id":"https://genegraph.clinicalgenome.org/r/918790a6-373f-4074-a87a-5c4d13227674","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.889C>T (p.Arg297Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118813"}}],"firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Ataxia, neuro-developmental delay, sensorineural hearing loss, seizures, renal salt-wasting","phenotypes":["obo:HP_0012758","obo:HP_0001250","obo:HP_0001251","obo:HP_0000127","obo:HP_0000365"],"sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/285811de-04c3-46c3-8d5f-6396e777d5fd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19289823","allele":{"id":"https://genegraph.clinicalgenome.org/r/992f37a8-2a04-4ed9-8355-f89bc6c55fae"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/f1745dad-08e2-450e-8dce-b5b33912bb5a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19289823","allele":{"id":"https://genegraph.clinicalgenome.org/r/918790a6-373f-4074-a87a-5c4d13227674"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypeFreeText":"Ataxia, neuro-developmental delay, sensorineural hearing loss, seizures, renal salt wasting","phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001250","obo:HP_0000127","obo:HP_0001251","obo:HP_0012758","obo:HP_0000365"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/577d3f1e-6367-4019-bf69-ae07c58c1b1b"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/577d3f1e-6367-4019-bf69-ae07c58c1b1b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/577d3f1e-6367-4019-bf69-ae07c58c1b1b"},{"id":"https://genegraph.clinicalgenome.org/r/285811de-04c3-46c3-8d5f-6396e777d5fd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/285811de-04c3-46c3-8d5f-6396e777d5fd_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/285811de-04c3-46c3-8d5f-6396e777d5fd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutating this variant causes a decrease in channel activity. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f1745dad-08e2-450e-8dce-b5b33912bb5a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1745dad-08e2-450e-8dce-b5b33912bb5a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f1745dad-08e2-450e-8dce-b5b33912bb5a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutation triggered a total lack of Kir 4.1 channel activity in mutant cells in an in-vitro model (PMID: 20678478, Tang et al., 2010). ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/a490bafa-1ea2-482a-920f-22d9683a5ff5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a490bafa-1ea2-482a-920f-22d9683a5ff5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19289823","rdfs:label":"Scholl et al., 2009: Individual 441","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/80f50be0-bc53-45b0-b9e8-72339ec473b9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002241.5(KCNJ10):c.491C>T (p.Thr164Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118811"}},"firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Ataxia, neuro-developmental delay, sensorineural hearing loss, renal salt-wasting","phenotypes":["obo:HP_0000127","obo:HP_0012758","obo:HP_0001251","obo:HP_0000407","obo:HP_0001250"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/10f4702e-0f59-4cf1-9419-3c869075772e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19289823","allele":{"id":"https://genegraph.clinicalgenome.org/r/80f50be0-bc53-45b0-b9e8-72339ec473b9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/10f4702e-0f59-4cf1-9419-3c869075772e","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10f4702e-0f59-4cf1-9419-3c869075772e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/10f4702e-0f59-4cf1-9419-3c869075772e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutation triggered a total lack of Kir 4.1 channel activity in mutant cells in an in-vitro model (PMID: 20678478, Tang et al., 2010). ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6c414bc-9642-4fe5-bdec-8d9c59c04c1f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43a4d33e-1b35-4258-81bf-1dd89e4d03cd","type":"Finding","dc:description":"Expression is especially high in the brain, which is characteristic of epilepsy. Also, there is some expression in the kidney, which makes sense for renal salt-wasting. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12618319","rdfs:label":"GTEx expression level data","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d0267781-f1de-41d1-a21b-2883d606d584","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8467e47-6148-4ae7-90d4-a3ce7e4ee6d4","type":"Finding","dc:description":"If sodium is not properly processed by the heterodimer, kidney salt wasting and therefore SESAME/EAST syndrome results. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33811157","rdfs:label":"KCNJ10/KCNJ16 Heterodimer","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/27660ccd-5616-4b2f-be79-45c4f9efdab1","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d091d624-08b4-4452-9364-5e6fb829e0de","type":"FunctionalAlteration","dc:description":"Patch-clamp tests were done to determine the level of channel activity in the mutants compared with that of the wild-type. The Ala201Thr mutant nearly completely stopped the flow of potassium into the cell through impairing the Kir4.1 channel subunit (protein encoded by KCNJ10), and the Ile209Thr mutation partially did. Impairment of Kir4.1 channel activity triggered by AlaThr201 might, partially or fully, be due to smaller amounts of Kir 4.1 overall and on the cell surface. The Ala201Thr variant did not impact the expression of the KCNJ10 gene, but influenced the resistance of the protein to breaking down. Kir4.1 with the Ala201Thr variant is broken down more readily in a lysosome-influenced mechanism. This these variants are associated with SESAME/EAST syndrome, as these variants were identified in two probands from the same family who both had SESAME/EAST syndrome and were compound heterozygous for the two variants in trans. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12618319","rdfs:label":"Hamster cultured cells "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/29ea43d4-6c86-4110-a34e-291fe56ec2c4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07fbd059-dcb0-4c06-bfb2-ecc70094c362","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aab224b5-e227-4190-91e9-e71aac96241c","type":"Finding","dc:description":"The hearing loss is a key symptom in SESAME/EAST. The mice had lots of trouble moving around when 8-10 days old, which the authors believe is an effect of spinal cord and brainstem myelination and formation of vacuoles of deep cerebellar nuclei soon after being born. \nn spinal cord and brainstem myelination as well as to vacuolation of deep cerebellar nuclei at early stages of development. Homozygous mutations notably lower the expression of Kir4.1 in comparison to the wildtype. In addition, in 2009, these same KCNJ10 knockout mice were evaluated for the kidney-related phenotype. The mice died around day 8. The mice experienced polyuria and renal salt-wasting. These symptoms were characteristic of the tubulopathy that the probands in this study experienced (Bockenhauer et al., 2009; PMID: 19420365). ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11466414","rdfs:label":"Inner ear structural issues/hearing loss in mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5}],"evidenceStrength":"Definitive","sequence":6563,"specifiedBy":"GeneValidityCriteria9","strengthScore":15.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/neZAy_u-xqE","type":"GeneValidityProposition","disease":"obo:MONDO_0013005","gene":"hgnc:6256","modeOfInheritance":"obo:HP_0000007"},"version":"1.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_29ea43d4-6c86-4110-a34e-291fe56ec2c4-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}